Press Releases

Press Releases

Date Title  
Dec 05, 2019
Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
DUBLIN, Ireland , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in the biotechnology
Nov 05, 2019
Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted cash position of $393.0 million provides funding to advance a diversified neuroscience pipeline DUBLIN, Ireland , Nov.
Oct 29, 2019
Prothena to Report Third Quarter 2019 Financial Results on November 5
DUBLIN, Ireland , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets.
Aug 06, 2019
Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $12.2 million in the second quarter and $29.7 million for the first six months of 2019; quarter-end cash and restricted cash position of $402.2 million provides funding to advance neuroscience pipeline Appointed Paula K.
Jul 30, 2019
Prothena to Report Second Quarter 2019 Financial Results on August 6
DUBLIN, Ireland , July 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2019 on August 6, 2019 after the close of the U.S. financial markets.
Jul 01, 2019
Prothena Announces Appointment of Paula K. Cobb to its Board of Directors
DUBLIN, Ireland , July 01, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of Directors. “As a biotechnology executive with wide-ranging global development, business strategy and
May 30, 2019
Prothena to Participate in the Jefferies Healthcare Conference
DUBLIN, Ireland , May 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6 th at 10:30 AM ET in New York,
May 07, 2019
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated cell line development of a lead candidate for preclinical tau program DUBLIN,
Apr 30, 2019
Prothena to Report First Quarter 2019 Financial Results on May 7
DUBLIN, Ireland , April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets.
Apr 18, 2019
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018 Results from post hoc analyses revealed a potential survival benefit with NEOD001 in the category of patients at the highest risk for early mortality ( Mayo Stage IV )